Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva®) in Combination With OSI-906 or Placebo in Chemonaive Patients With Advanced NSCLC With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NCT01221077 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01221077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01221077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva®) in Combination With OSI-906 or Placebo in Chemonaive Patients With Advanced NSCLC With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
April 8, 2011
Completion date
September 1, 2014
Enrollment
88 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, nsclc